ecancermedicalscience

Case Report

Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib

17 May 2018
Kai Sun, Saro Kasparian, Swaminathan Iyer, Sai Ravi Pingali

Ibrutinib, a Bruton’s tyrosine kinase inhibitor, has been increasingly widely used in relapsed and refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukaemia [1, 2]. With its use becoming more common, there have been emerging case reports of opportunistic infections like cryptococcal infections [3–8]. These infections in patients receiving ibrutinib were mostly reported in patients with chronic lymphocytic leukaemia, who have poor immune reconstitution. Here, we report two cases of cryptococcal meningoencephalitis in patients with MCL on ibrutinib.

Related Articles

Eduardo Payet, Joan Perez, Gustavo Sarria, Silvia Neciosup, Francisco Berrospi, Sheila Vilchez, Jorge Dunstan, Ronald Perez, Mauricio Vassallo, Santiago Salgado, Nanto Caparachín, Joseph A Pinto, Alexis Holguin
Chandrayee Sarker, Vivek S Radhakrishnan, Paya Mandal, Jeevan Kumar, Saurabh Bhave, Rimpa Achari, Debdeep Dey, Indu Arun, Zameer Latif, Neeraj Arora, Deepak Mishra, Mammen Chandy, Reena Nair
Ann Abiola Ogbenna, Olufemi Abiola Oyedeji, Christiana Oluwakemi Famuyiwa, Babajide Ayodeji Sopekan, Obadiah Dapus Damulak, Esere Bernice Akpatason, Gbenga Olorunfemi, Kehinde Adekola
Mahwish Faizan, Saadia Anwar, Rahat Ul Ain, Huma Zafar, Nazish Saqlain, Zunaira Rathore
Clement D Okello, Yusuf Mulumba, Abrahams Omoding, Henry Ddungu, Jackson Orem
Ntokozo Ndlovu, Sandra Ndarukwa, Albert Nyamhunga, Patience Musiwa-Mba, Anna Mary Nyakabau, Webster Kadzatsa, Melinda Mushonga